A feasibility study of intensive CAF as outpatient adjuvant therapy for stage II breast cancer in a cooperative group: CALGB 8443

Daniel R. Budman, Ann Hughes Korzun, Joseph Aisner, Jerry Younger, Richard Silver, Mary Costanza, Mary Alice Rice, William Wood

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

In preparation for a national Phase III say of dose and dose intensity in the treatment of node-positive, Stage II adenocarcinoma of the female breast, CALGB instituted a pilot study of intensive intravenous outpatient CAF (cyclophosphamide, Adriamycin, 5-fluorouracil) for four months. This study was designed to give full doses of drugs without dose reduction for hematologic toxicity. In order to evaluate the feasibility of physician and patient compliance with a potentially toxic therapy, a multi-institution pilot study was performed. lEs protocol demonstrated that a cooperative group could deliver toxic drug doses to outpatients with a median of 98% of cyclophosphamide, 97% of Adriamycin (doxorubicin), and 91% of 5-fluorouracil administered on schedule. Major side effects, as expected, were leukopenia, nausea, and vomiting. Disease-free survival is at least equivalent to that observed in previous studies.

Original languageEnglish (US)
Pages (from-to)571-575
Number of pages5
JournalCancer Investigation
Volume8
Issue number6
DOIs
StatePublished - Jan 1 1990

Fingerprint

Feasibility Studies
Fluorouracil
Doxorubicin
Cyclophosphamide
Outpatients
Poisons
Breast Neoplasms
Leukopenia
Patient Compliance
Pharmaceutical Preparations
Nausea
Disease-Free Survival
Vomiting
Appointments and Schedules
Adenocarcinoma
Breast
Therapeutics
Physicians

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Budman, Daniel R. ; Korzun, Ann Hughes ; Aisner, Joseph ; Younger, Jerry ; Silver, Richard ; Costanza, Mary ; Rice, Mary Alice ; Wood, William. / A feasibility study of intensive CAF as outpatient adjuvant therapy for stage II breast cancer in a cooperative group : CALGB 8443. In: Cancer Investigation. 1990 ; Vol. 8, No. 6. pp. 571-575.
@article{0a3dc408e54c4397b13d393cd5c1f66f,
title = "A feasibility study of intensive CAF as outpatient adjuvant therapy for stage II breast cancer in a cooperative group: CALGB 8443",
abstract = "In preparation for a national Phase III say of dose and dose intensity in the treatment of node-positive, Stage II adenocarcinoma of the female breast, CALGB instituted a pilot study of intensive intravenous outpatient CAF (cyclophosphamide, Adriamycin, 5-fluorouracil) for four months. This study was designed to give full doses of drugs without dose reduction for hematologic toxicity. In order to evaluate the feasibility of physician and patient compliance with a potentially toxic therapy, a multi-institution pilot study was performed. lEs protocol demonstrated that a cooperative group could deliver toxic drug doses to outpatients with a median of 98{\%} of cyclophosphamide, 97{\%} of Adriamycin (doxorubicin), and 91{\%} of 5-fluorouracil administered on schedule. Major side effects, as expected, were leukopenia, nausea, and vomiting. Disease-free survival is at least equivalent to that observed in previous studies.",
author = "Budman, {Daniel R.} and Korzun, {Ann Hughes} and Joseph Aisner and Jerry Younger and Richard Silver and Mary Costanza and Rice, {Mary Alice} and William Wood",
year = "1990",
month = "1",
day = "1",
doi = "10.3109/07357909009018922",
language = "English (US)",
volume = "8",
pages = "571--575",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "6",

}

A feasibility study of intensive CAF as outpatient adjuvant therapy for stage II breast cancer in a cooperative group : CALGB 8443. / Budman, Daniel R.; Korzun, Ann Hughes; Aisner, Joseph; Younger, Jerry; Silver, Richard; Costanza, Mary; Rice, Mary Alice; Wood, William.

In: Cancer Investigation, Vol. 8, No. 6, 01.01.1990, p. 571-575.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A feasibility study of intensive CAF as outpatient adjuvant therapy for stage II breast cancer in a cooperative group

T2 - CALGB 8443

AU - Budman, Daniel R.

AU - Korzun, Ann Hughes

AU - Aisner, Joseph

AU - Younger, Jerry

AU - Silver, Richard

AU - Costanza, Mary

AU - Rice, Mary Alice

AU - Wood, William

PY - 1990/1/1

Y1 - 1990/1/1

N2 - In preparation for a national Phase III say of dose and dose intensity in the treatment of node-positive, Stage II adenocarcinoma of the female breast, CALGB instituted a pilot study of intensive intravenous outpatient CAF (cyclophosphamide, Adriamycin, 5-fluorouracil) for four months. This study was designed to give full doses of drugs without dose reduction for hematologic toxicity. In order to evaluate the feasibility of physician and patient compliance with a potentially toxic therapy, a multi-institution pilot study was performed. lEs protocol demonstrated that a cooperative group could deliver toxic drug doses to outpatients with a median of 98% of cyclophosphamide, 97% of Adriamycin (doxorubicin), and 91% of 5-fluorouracil administered on schedule. Major side effects, as expected, were leukopenia, nausea, and vomiting. Disease-free survival is at least equivalent to that observed in previous studies.

AB - In preparation for a national Phase III say of dose and dose intensity in the treatment of node-positive, Stage II adenocarcinoma of the female breast, CALGB instituted a pilot study of intensive intravenous outpatient CAF (cyclophosphamide, Adriamycin, 5-fluorouracil) for four months. This study was designed to give full doses of drugs without dose reduction for hematologic toxicity. In order to evaluate the feasibility of physician and patient compliance with a potentially toxic therapy, a multi-institution pilot study was performed. lEs protocol demonstrated that a cooperative group could deliver toxic drug doses to outpatients with a median of 98% of cyclophosphamide, 97% of Adriamycin (doxorubicin), and 91% of 5-fluorouracil administered on schedule. Major side effects, as expected, were leukopenia, nausea, and vomiting. Disease-free survival is at least equivalent to that observed in previous studies.

UR - http://www.scopus.com/inward/record.url?scp=0025684785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025684785&partnerID=8YFLogxK

U2 - 10.3109/07357909009018922

DO - 10.3109/07357909009018922

M3 - Article

C2 - 2292049

AN - SCOPUS:0025684785

VL - 8

SP - 571

EP - 575

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 6

ER -